275 related articles for article (PubMed ID: 15999121)
1. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Quinn JE; Brown LG; Zhang J; Keller ET; Vessella RL; Corey E
Prostate Cancer Prostatic Dis; 2005; 8(3):253-9. PubMed ID: 15999121
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Corey E; Brown LG; Quinn JE; Poot M; Roudier MP; Higano CS; Vessella RL
Clin Cancer Res; 2003 Jan; 9(1):295-306. PubMed ID: 12538482
[TBL] [Abstract][Full Text] [Related]
4. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
5. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
6. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
13. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.
Tanaka T; Kawashima H; Ohnishi K; Matsumura K; Yoshimura R; Matsuyama M; Kuratsukuri K; Nakatani T
Anticancer Res; 2009 Apr; 29(4):1089-94. PubMed ID: 19414350
[TBL] [Abstract][Full Text] [Related]
14. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
16. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
20. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]